singular genomics is a venture capital backed biotech company in la jolla, california. we foster a dynamic, fast paced, result oriented environment where we offer employees the opportunity to make a significant impact in a rapidly expanding company. singular genomics is inventing at the forefront of genomics, one of the world’s fastest growing industries. we are located in the center of the biotech hub on the torrey mesa close to the pacific ocean and next door to prestigious institutions like the salk institute, scripps, sanford burnham, and ucsd. we offer free gym membership, 401k plan, competitive health benefits, flexible vacation, and equity incentives, so you can grow as the company grows. we are working to accelerate genomics for the advancement of science and medicine and are passionate about the potential of genomics for improving human health.
Company profile
Ticker
OMIC
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
812948451
OMIC stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
18 Apr 24
DEFA14A
Additional proxy soliciting materials
18 Apr 24
DEF 14A
Definitive proxy
18 Apr 24
PRE 14A
Preliminary proxy
5 Apr 24
S-8
Registration of securities for employees
18 Mar 24
10-K
2023 FY
Annual report
18 Mar 24
8-K
Singular Genomics Reports Recent Highlights and Fourth Quarter and Full Year 2023 Financial Results
18 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
19 Jan 24
8-K
Singular Genomics Reports Instrument Shipments and Preliminary Unaudited Fourth Quarter 2023 Revenue
8 Jan 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
Transcripts
OMIC
Earnings call transcript
2023 Q4
18 Mar 24
OMIC
Earnings call transcript
2023 Q3
14 Nov 23
OMIC
Earnings call transcript
2023 Q2
9 Aug 23
OMIC
Earnings call transcript
2023 Q1
9 May 23
OMIC
Earnings call transcript
2022 Q4
2 Mar 23
OMIC
Earnings call transcript
2022 Q3
8 Nov 22
OMIC
Earnings call transcript
2022 Q2
13 Aug 22
OMIC
Earnings call transcript
2022 Q1
15 May 22
OMIC
Earnings call transcript
2021 Q4
3 Mar 22
OMIC
Earnings call transcript
2021 Q3
14 Nov 21
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 35.01 mm | 35.01 mm | 35.01 mm | 35.01 mm | 35.01 mm | 35.01 mm |
Cash burn (monthly) | 13.84 mm | 5.00 mm | 8.18 mm | 8.34 mm | 5.60 mm | 6.22 mm |
Cash used (since last report) | 95.97 mm | 34.65 mm | 56.72 mm | 57.82 mm | 38.87 mm | 43.15 mm |
Cash remaining | -60.96 mm | 360.28 k | -21.71 mm | -22.81 mm | -3.85 mm | -8.14 mm |
Runway (months of cash) | -4.4 | 0.1 | -2.7 | -2.7 | -0.7 | -1.3 |
Institutional ownership, Q2 2023
69.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 66 |
Opened positions | 15 |
Closed positions | 19 |
Increased positions | 16 |
Reduced positions | 21 |
13F shares | Current |
---|---|
Total value | 27.26 bn |
Total shares | 51.21 mm |
Total puts | 14.70 k |
Total calls | 12.50 k |
Total put/call ratio | 1.2 |
Largest owners | Shares | Value |
---|---|---|
Flynn James E | 8.98 mm | $0.00 |
Deerfield Management | 6.45 mm | $5.35 bn |
UBS UBS Group AG - Registered Shares | 4.68 mm | $3.88 bn |
Domain Partners IX | 4.40 mm | $50.81 mm |
Arch Venture | 3.80 mm | $3.15 bn |
ARCH Venture Fund IX | 3.80 mm | $43.92 mm |
Perceptive Advisors | 2.36 mm | $1.96 bn |
FMR | 2.12 mm | $1.76 bn |
Vanguard | 1.89 mm | $1.57 bn |
Coatue Management | 1.68 mm | $1.39 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Mar 24 | Sam Ropp | Common Stock | Option exercise | Acquire M | No | No | 0 | 4,187 | 0.00 | 16,750 |
15 Mar 24 | Sam Ropp | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 4,187 | 0.00 | 50,250 |
15 Mar 24 | Dalen Meeter | Common Stock | Option exercise | Acquire M | No | No | 0 | 6,250 | 0.00 | 200,273 |
15 Mar 24 | Dalen Meeter | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 6,250 | 0.00 | 75,000 |
15 Mar 24 | Eli N. Glezer | Common Stock | Option exercise | Acquire M | No | No | 0 | 7,500 | 0.00 | 4,585,000 |
15 Mar 24 | Eli N. Glezer | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 7,500 | 0.00 | 90,000 |
15 Mar 24 | Andrew Spaventa | Common Stock | Gift | Acquire G | Yes | No | 0 | 14,583 | 0.00 | 4,090,372 |
15 Mar 24 | Andrew Spaventa | Common Stock | Gift | Dispose G | No | No | 0 | 14,583 | 0.00 | 9,766 |
15 Mar 24 | Andrew Spaventa | Common Stock | Option exercise | Acquire M | No | No | 0 | 14,583 | 0.00 | 24,349 |
15 Mar 24 | Andrew Spaventa | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 14,583 | 0.00 | 175,000 |
News
Singular Genomics Sys: Q4 Earnings Insights
18 Mar 24
Singular Genomics Sys Q4 2023 GAAP EPS $(0.32) Beats $(0.36) Estimate, Sales $1.081M Beat $731.333K Estimate
18 Mar 24
Earnings Scheduled For March 18, 2024
18 Mar 24
Preview: Singular Genomics Sys's Earnings
15 Mar 24
12 Health Care Stocks Moving In Friday's After-Market Session
9 Feb 24
Press releases
Singular Genomics Reports Recent Highlights and Fourth Quarter and Full Year 2023 Financial Results
18 Mar 24
Singular Genomics to Report Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024
4 Mar 24
Singular Genomics Showcases New G4X™ Spatial Sequencer at AGBT and Announces Significant Advances in Throughput, Quality, and Usability for G4® Sequencing Platform
5 Feb 24
Singular Genomics Unveils G4X™ Spatial Sequencer, Transforming the Landscape of In Situ Multiomic Analysis
5 Feb 24